Building on a New Approach to Validate Gene Editing and Localize CAR Cassettes in T Cells

Viral Vector therapies are gaining increasing traction with more and more companies looking to take the leap from other Biologics. In the early stages of clinical development, it’s expedient to outsource to de-risk the venture.

Pharmaron has taken their platform beyond small molecules and are pleased to now offer a full array of services for biologics and cell and gene therapies (CGTs). Our new CGT webinar series focusses on identifying key cell and gene therapy questions that arise during drug discovery and development.

Tumor heterogeneity is a major hurdle for cancer treatment success. To effectively enroll patients in clinical trials, the identification of predictive biomarkers at the preclinical stage is crucial. The use of patient-derived xenograft (PDX) tumor models facilitates the identification of biomarkers that predict the tumor’s response to therapy. In addition, the assessment of PDX models on broad screening platforms such as 3D culture and in vivo mouse clinical trials (humanized and immunodeficient) accelerates compound evaluation. This webinar discusses the use of PDX models in preclinical drug development and the benefits of using this approach to clinical trial outcomes. Click below to view the slides of the presentation.

Human induced pluripotent stem cells (hiPSCs) have been globally recognized as a multipurpose research tool for modeling human disease and biology, screening and developing potential therapeutic drugs, and implementing cell and gene therapies. The ability to differentiate human iPSCs into any cell type supports the study of biology and disease in these specified cells in vitro.